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Since 2009 pandemic, international health authorities recommended monitoring severe and complicated cases of respiratory
disease, that is, severe acute respiratory infection (SARI) and acute respiratory distress syndrome (ARDS). We evaluated the
proportion of SARI/ARDS cases and deaths due to influenza A(H1N1)pdm09 infection and the impact of other respiratory viruses
during pandemic and postpandemic period (2009–2011) in northern Italy; additionally we searched for unknown viruses in those
cases for which diagnosis remained negative. 206 respiratory samples were collected from SARI/ARDS cases and analyzed by real-
time RT-PCR/PCR to investigate influenza viruses and other common respiratory pathogens; also, a virus discovery technique
(VIDISCA-454) was applied on those samples tested negative to all pathogens. Influenza A(H1N1)pdm09 virus was detected in
58.3% of specimens, with a case fatality rate of 11.3%. The impact of other respiratory viruses was 19.4%, and the most commonly
detected viruses were human rhinovirus/enterovirus and influenza A(H3N2). VIDISCA-454 enabled the identification of one
previously undiagnosed measles infection. Nearly 22% of SARI/ARDS cases did not obtain a definite diagnosis. In clinical practice,
great efforts should be dedicated to improving the diagnosis of severe respiratory disease; the introduction of innovative molecular
technologies, as VIDISCA-454, will certainly help in reducing such “diagnostic gap.”
1. Introduction
Most cases of influenzaA(H1N1)pdm09 infection have amild
outcome; however some present as severe acute respiratory
infection (SARI) and require admission to intensive care
unit (ICU) [1, 2]. The main reason for admission to ICU
is a pulmonary inflammatory syndrome characterized by
diffuse alveolar damage (acute respiratory distress syndrome:
ARDS), which can be fatal. Since the beginning of 2009 pan-
demic, international health authorities recommended mon-
itoring severe and complicated cases of influenza infection
[3, 4]. Considering the serious outcome of these respiratory
diseases, the contribution of other respiratory pathogens
besides A(H1N1)pdm09 should be envisaged [5]. Addition-
ally, in clinical practice, a specific causative agent which
explains the respiratory symptoms is often unidentified,
owing to the lack of sensitive tests or the presence of an as-
yet unknown pathogen. The recently developed VIDISCA-
454 (VIrus DIScovery using CDNA Amplified fragment-length
polymorphism combined with Roche-454 high-throughput
sequencing) is a sensitive sequence-independent virus dis-
covery techniquewhich can be used to reveal as-yet unknown
viruses [5, 6].
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This study aimed at evaluating the proportion of
SARI/ARDS cases and deaths due to A(H1N1)pdm09 infec-
tion and assessing the impact of other respiratory pathogens
during pandemic and postpandemic period (2009–2011) in
northern Italy as well as searching for unknown viruses in
those cases for which diagnosis remained negative. To this
end, common respiratory pathogens were investigated and
VIDISCA-454 methodology was applied on samples which
remained negative for all tested pathogens.
2. Materials and Methods
In the capacity of reference laboratory operating within
InfluNet network [7], our laboratory is in charge of carrying
out the virological surveillance of severe forms of influenza
infection in Lombardy (nearly 10 million inhabitants). From
October 1, 2009, to April 30, 2011, 206 respiratory samples
were collected from patients hospitalized due to severe
respiratory illness. Of these, 61.2% were males with a median
age of 44.3 years (IQR: 49.7 years; range: 1 month–89 years);
17.5% were children ≤ 5 years and 23.3% were ≥65 years.
Data on comorbidities presence were available for nearly
70% of study patients: 64.3% reported medical conditions
[3, 4]; in detail, 25.6% had weakened immune system (due
to cancer, HIV/AIDS, or long-term steroid treatment), 19.7%
heart disease, 11.6% asthma/chronic lung disease, and 10.4%
neurological/neurodevelopmental conditions. Out of 206
patients, 91 (59.3% males; 18.7% aged ≤ 5 years, 58.2% aged
6–64 years) were SARI cases who required admission to ICU
and extracorporealmembrane oxygenation (ECMO) therapy,
and 115 (62.6% males; 16.5% aged ≤ 5 years, 60% aged 6–
64 years) were ARDS cases, as defined by the European
Consensus Conference [8]. Nine ARDS patients (median age:
35.6 years, IQR: 21.4 years) died during hospitalization: case
fatality rate (CFR) in our ARDS series was 7.8% (9/115). No
SARI case was fatal.
Respiratory specimens (paired nasal/oral swab and bron-
choalveolar lavage) were collected from each SARI/ARDS
case. Nucleic acids were purified by NucliSENS easyMAG
(bioMe´rieux, France) and analyzed by real-time RT-PCR
assay to identify influenza virus. In detail, a one-step real-
time RT-PCR assay was performed to simultaneously detect
influenza viruses type A and B [9].The subtyping of influenza
A positive samples was carried out by a one-step real-
time RT-PCR assay using specific primer/probe sets for the
hemagglutinin gene [10].
The clinical specimens that resulted negative to influenza
virus detection were then screened by real-time RT-
PCR/PCR for a panel of respiratory pathogens (Respira-
tory MWS r-gene Real-time PCR, bioMe´rieux, France) to
detect respiratory syncytial virus (RSV) A and B; human
metapneumovirus (hMPV) A and B; human rhinovirus
(hRV) and enterovirus (hEV); adenovirus (AdV); human
bocavirus (hBoV) 1–4; human coronavirus (hCoV) 229E,
NL63, OC43, HKU1; human parainfluenza virus (hPIV) 1–4;
Chlamydophila pneumoniae; Mycoplasma pneumoniae.
Cases which resulted negative to all diagnostic assays
were further investigated by VIDISCA-454 technique. This
Table 1: Impact of respiratory pathogens on the patients with
SARI/ARDS (𝑁 = 206).
Pathogen
Number of positive samples
SARI
(𝑁 = 91)
ARDS
(𝑁 = 115)
SARI/ARDS
(𝑁 = 206)
Influenza
A(H1N1)pdm09 virus 58 62 120
hRV/hEV 7 4 11
Influenza A(H3N2) virus 7 1 8
RSV 3 1 4
hCoV 2 2 4
hPIV 2 2 4
AdV 2 0 2
Influenza B virus 1 0 1
hBoV 1 0 1
hMPV 0 0 0
Chlamydophila
pneumoniae 0 0 0
Mycoplasma pneumoniae 0 0 0
Coinfections 2 3 5
is a virus discovery method based on recognition of restric-
tion enzyme cleavage sites, ligation of adaptors, and subse-
quent amplification by PCR combined with high-throughput
sequencing 454 FLX/Titanium system (Roche, USA) [5].
3. Results
Influenza A(H1N1)pdm09 virus was detected in 58.3%
(120/206) of SARI/ARDS cases (61.7% males; 13.3% aged
≤ 5 years, 67.5% aged 6–64 years). Moreover, the pres-
ence of another condition possibly increasing the risk
for developing influenza-related complications [3, 4] was
acknowledged for nearly half of A(H1N1)pdm09-positive
SARI/ARDS cases: 25.4% had weakened immune system,
15.2% had heart disease, 11.9% were morbidly obese people
(body mass index ≥ 40), 10.2% had asthma/chronic lung
disease or neurological/neurodevelopmental conditions, and
4.2% were pregnant women. Approximately half (62/120:
51.7%) of A(H1N1)pdm09-positive patients had ARDS. It
is worth mentioning that A(H1N1)pdm09 was identified
in 77.8% (7/9) of fatal ARDS cases (42.9% males, median
age: 30.4 years, IQR: 15.4 years). Four (4/7: 57.1%) of these
individuals belonged to risk categories (i.e., two were cancer
patients, one was morbidly obese, and one had underlying
neurodevelopmental conditions). Thus, the A(H1N1)pdm09
CFR was 11.3% (7/62).
The impact of respiratory pathogens other than
A(H1N1)pdm09 was 19.4% (40/206) (65% males; 30%
aged ≤ 5 years, 47.5% aged 6–64 years). HRV/hEV were
the most frequently identified viruses followed by influenza
A(H3N2) virus, accounting for 27.5% (11/40) and 20% (8/40)
of infections, respectively (Table 1). No fatal cases were
ascribable to pathogens other than A(H1N1)pdm09.
BioMed Research International 3
206
SARI/ARDS 
cases 
Number of fatal cases: 9
Number of fatal cases: 7
86 SARI/ARDS
46 SARI/ARDS
cases negative to 
cases negative to 
all known viruses
45 (21.8%)    
SARI/ARDS cases with SARI/ARDS cases with 
unknown diagnosis
161 (78.2%) 
known diagnosis
1 measles infection
40 (46.5%) 
cases of other
cases of
120 (58.3%)
Real-time PCRs/RT-PCRs  
Real-time PCR 
A(H1N1)pdm09
 for A(H1N1)pdm09
A(H1N1)pdm09
for respiratory viruses respiratory viruses
VIDISCA-454
Number of fatal cases: 2
Number of fatal cases: 0
Number of fatal cases: 2
Number of fatal cases: 7 Number of fatal cases: 2
Number of fatal cases: 0
Figure 1: Study design and results overview.
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Forty-six (46/206: 22.3%) SARI/ARDS cases (including
two fatalities) resulted negative to all diagnostic assays (58.2%
males; 18.2% aged ≤ 5 years, 45.4% aged 6–64 years) and
were further investigated by VIDISCA-454 [5, 11]. VIDISCA-
454 revealed no sequence reads that could belong to a novel
virus or viral variant in any of the 46 specimens; however
it enabled the identification of one case of undiagnosed
measles, thus increasing the proportion of cases with a
diagnosis to 78.2% (161/206). Hence, the overall proportion
of cases with unknown diagnosis was 21.8% (45/206); most
(34/45: 75.6%) cases that could not be diagnosed were ARDS
and two (2/45: 4.4%) were fatal. Figure 1 summarizes study
results.
4. Discussion
During pandemic and postpandemic period, several path-
ogens cocirculated and were associated to severe respiratory
infections; however, influenza A(H1N1)pdm09 virus had the
greatest impact (58.3%) in our SARI/ARDS series. More than
half (51.7%) of A(H1N1)pdm09 infection resulted in ARDS.
It is interesting to note that most (67.5%) severe respiratory
diseases due to A(H1N1)pdm09 infection were identified
among 6–64-year-old individuals. The A(H1N1)pdm09 case
fatality rate in our ARDS series was 11.3% fatal cases in young
adults, and 42.8% did not belong to any at-risk category [3, 4].
This data is in agreement with other studies; Van Kerkhove
et al. have reported a median age of 46 years among fatal
laboratory-confirmed A(H1N1)pdm09 cases [12]. McCallum
has described that during the 2009 pandemic only 1% of
laboratory-confirmed cases and 13% of laboratory-confirmed
deaths were among persons 65 years of age or older [13]. The
Global PandemicMortality (GLaMOR) project has evaluated
that although the pandemic mortality estimate was similar
in magnitude to that of seasonal influenza, a marked shift
toward mortality among persons 65 years of age occurred,
so that many more life-years were lost [14]. Such an age
shift has been documented as well by several studies on
A(H1N1)pdm09 mortality [15–17].
The proportion of SARI/ARDS cases associated with
respiratory viruses other than A(H1N1)pdm09 was signifi-
cantly lower (19.4% versus 58.3%,𝑃 value<0.0000001). Severe
respiratory diseases associated with respiratory viruses other
than A(H1N1)pdm09 were detected more frequently among
children ≤ 5 years (13.3% versus 30%, 𝑃 value = 0.02). This
piece of evidence is in accordance with the results of other
studies reporting a notable burden of respiratory viruses in
children under 5 years [18–20].
Studies published to date have suggested that influenza
viruses and rhinoviruses are the leading causes of severe
respiratory disease leading to hospitalization [21, 22], simi-
larly to what was observed in our SARI/ARDS series, where
hRV/hEV were the most common identified viruses along
with influenza viruses. Also influenza A(H3N2) virus played
a significant role in our SARI cases and caused ARDS
in one patient with a weakened immune system due to
HIV/AIDS. Overall, the proportion of SARI/ARDS corre-
lated to an influenza A virus infection was 62.1% (128/206),
thus emphasizing the central role of influenza A virus in
severe respiratory infection [23, 24].
The use of molecular assay has notably contributed to
identifying pathogens possibly involved in severe respiratory
disease, thus allowing getting to a diagnosis of viral infection
in nearly 80% of study SARI/ARDS cases. Other studies that
have not used nucleic acid amplification assays have typically
reported that 5–20% of cases of acute respiratory infection
have a viral etiology [25]. In addition, it is noteworthy
that VIDISCA-454 enabled the identification of one measles
infection that escaped clinical diagnosis in one SARI case.
Hence, measles infection should be considered in compli-
cated pulmonary disease, as also suggested by others [26],
since measles virus is not generally included in respiratory
diagnostic panels.
5. Conclusions
During pandemic and postpandemic period, several path-
ogens cocirculated and were associated to severe respiratory
infections, with influenza A(H1N1)pdm09 virus having the
greatest impact. Nearly 22% of SARI/ARDS cases did not
obtain a definite diagnosis, and among these cases two were
fatal. In clinical practice, great efforts should be devoted to
improving diagnosis of severe respiratory infec-tions and to
reducing such “diagnostic gap.” The advantage from relying
upon more accurate diagnosis could benefit the patient,
in terms of receiving the more appropriate antiviral drugs,
and could provide more detailed information on viruses
circulating in the community, thus making public health
authorities aware so as to adjust their policies accordingly.
VIDISCA-454 proved to be a sensitive and specific
methodology that can be successfully applied to surveillance
of viral respiratory infections that represent an ever-changing
field due to the continuous emergence of new viruses (i.e.,
influenza A(H5N1) and A(H7N9) viruses, MERS-CoV).
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